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Abstract
Transdermal scopolamine has been shown to be very useful in the management of drooling, particularly in patients 
with neurological or neuropsychiatric disturbances or severe developmental disorders. In this paper, we present the 
case of a 24-year-old patient with a diagnosis of cerebral palsy and a severe problem of drooling, exacerbated by 
marked mandibular prognathism. After exclusion of other therapeutic alternatives, it was decided to use sustained-
release transdermal scopolamine patches (Scopoderm TTS). This technique consists of the application every three 
days of a patch with 1.5 mg of scopolamine in the area of the mastoid apophysis; the patch releases a dose of 0.5 mg 
of the active substance over each 24 hour period. The patient underwent periodic clinical and laboratory follow-up 
over a period of three years, achieving satisfactory results with no significant undesirable effects.
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Introduction
The terms hypersecretion, hypersalivation or ptyalism are 
used to describe the increase in salivary flow above normal 
limits (1,2). This can occur in physiological situations or 
in the context of a pathological process. The term sialo-
rrhoea refers to a symptom consisting of the sensation of 
increased salivary flow (1,3); true sialorrhoea occurs due 
to an excessive stimulus of the salivary reflex whereas, in 
contrast, false sialorrhoea or drooling is generally due to 
a difficulty in swallowing the saliva, which finally escapes 
through the lips (3).
Drooling is usually associated with a dysfunction of oral 
motor activity, an insufficient swallowing capacity, a 
deficient oral sphincter or, less frequently, with hypersali-
vation (4). It is a relatively common problem in disabled 
individuals and has significant physical, psychosocial 
and aesthetic repercussions. In severe cases, it can even 
lead to situations of dehydration and favour the onset of 
infections (5). Drooling also leads to an increase in the 
care needs in these patients, who require their clothes and 
protective bibs to be changed up to 15 times a day and, 
on occasions, require a towel placed permanently around 
their neck (6).
A number of treatments has been proposed in order to 
palliate the problem of  salivary hypersecretion and/or 
drooling, from techniques of  motor re-education and 
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physiotherapy to radical surgical procedures or radio-
therapy (2,4,5) (table 1). The possible pharmacological 
approaches include particularly the products used in 
gastro-oesophageal reflux (ranitidine, cisapride, etc.) and 
the anticholinergic drugs (propantheline bromide, glyco-
pyrrolate, etc), which include scopolamine.
Scopolamine basically has antiemetic and sedative-hypno-
tic properties. It has a duration of action of 5 to 6 hours 
after oral or parenteral administration, whereas its effect is 
maintained for 24-72 hours when it is administered in the 
form of transdermal patches. Its indications include the 
reduction of salivary secretion by blocking the parasym-
pathetic innervation of the salivary glands (7).
The objective of this paper is to describe the treatment of 
drooling by the application of transdermal scopolamine skin 
patches in a patient with a diagnosis of cerebral palsy.
Case Report
A 24-year-old male patient with a diagnosis of  cere-
bral palsy and psychomotor retardation. The family 
had requested medical consultation due to a problem 
of drooling that required changing the bib every hour. 
Physical examination of the patient confirmed the pre-
sence of drooling, exacerbated by a dolichofacial pattern 
characterised by significant mandibular prognathism, 
maxillary hypoplasia and an anterior open bite (figure 
1). The lack of collaboration on the part of the patient 
meant that treatments requiring his active participation, 
such as physiotherapy or behavioural control techniques, 
could not be considered. Although the surgical transposi-
tion of the ducts of the submaxillary salivary glands was 
initially contemplated as the best therapeutic alternative, 
this approach was excluded after consultation with the 
Maxillofacial Surgery Department, due to the need to 
perform bimaxillary orthognathic surgery to optimise 
the result of the transposition. It was finally decided to 
use transdermal scopolamine patches (Scopoderm TTS, 
Novartis Consumer Health, Paris) to treat the drooling
This technique consists of the application of a skin pa-
tch behind the ear, at the level of the mastoid apophysis 
(figure 2). The patch releases a sustained dose of 0.5 mg 
of scopolamine per day and must be changed every 72 
hours, alternating between the right and left sides at each 
change. Clinical follow-up was performed at the start of 
treatment and at two weeks, one month, six months and 
annually thereafter. Due to the limited collaboration of 
the patient, the clinical scale described by Thomas-Stonell 
and Greenburg (8) was used to quantify the drooling. 
TREATMENT ADVANTAGES DISADVANTAGES 
Motor re-education 
(physiotherapy, motor 
stimulation, logopedia, etc) 
- Non-invasive - Requires the collaboration of the 
patient/tutors 
- Relatively unpredictable results 
Pharmacological treatments 
(glycopyrrolate, benztropine, 
scopolamine, etc) 
- Non-invasive 
- Do not require collaboration 
- Adverse effects: irritability, 
sedation, mydriasis, urinary 
retention, etc. 
Surgical treatments 
(ligation, relocation of the ducts, 
excision of the glands, etc) 
- Do not require collaboration 
- High level of efficacy 
- Invasive technique 
- Require general anaesthesia 
- Adverse effects: rampant caries, 
mucositis, etc. 
Botulinum toxin 
- High efficacy 
- Simpler and less aggressive 
technique than the surgical 
treatments 
- May require general anaesthesia 
- Risk of muscle or nerve lesion in 
the adjacent regions 
Radiotherapy 
- Non-invasive 
- Does not require collaboration 
- Adverse effects: 
osteoradionecrosis, rampant 
caries, mucositis, etc. 
Photocoagulation of the salivary 
ducts 
- Simpler and less aggressive 
technique than the surgical 
treatments 
- Few statistical data 
- Adverse effects: postoperative 
inflammation and/or haematoma, 
cystic lesions, infections, etc. 
Lingual acupuncture 
- Simpler and less aggressive 
technique and the surgical 
treatments 
- Few statistical data 
- Requires collaboration 
Table 1. Therapeutic alternatives for the control of salivary drooling.
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This scale classifies drooling into five grades: 1 = dry (no 
drooling); 2 = mild (humid lips); 3 = moderate (wet lips 
and chin); 4 = severe (clothes slightly damp); 5 = profuse 
(clothes, hands and objects are wet).
The clinical follow-up was completed by 6-monthly con-
sultations with the family doctor, the neurologist and the 
ophthalmologist.
Blood tests (glucose, urea, creatinine, transaminases and 
electrolytes) were also performed to check for possible 
adverse effects that could initially be asymptomatic. The 
first blood test was performed before the first skin patch 
was applied, being repeated at 15 days, 3 months, 6 months 
and, subsequently, annually.
A significant reduction was detected in the drooling within 
24 hours after the application of the first patch, and con-
firmed by the reduction in the number of bibs used each 
day (from 6/day to 1/day). After one week of treatment, 
Fig. 1. Facial morphology of the patient (frontal and profile).
Fig. 2. Detail of the application of the 
scopolamine skin patch.
the severity of the drooling fell from grade 4 to grade 2. 
One year after having started the treatment, the degree 
of drooling remained at grade 2, and the use of bibs was 
no longer necessary. After three years of treatment, the 
same therapeutic effect is maintained, with a degree of 
drooling of grade 1-2. Although mild oliguria has been 
observed, no adverse effect that requires the suspension 
of the treatment has been detected to date.
Discussion
A number of studies have shown a reduction in salivary 
secretion secondary to the administration of scopolamine 
(9-11). Scopolamine has therefore been used with this aim 
in a number of medical specialities, including Dentistry, 
Otorhinolaryngology and Palliative care, and in certain 
neurological disorders (9,10). The use of the transdermal 
route effectively reduces salivary secretion in approxima-
tely 67% of patients, and its effects can be observed within 
15 minutes of application (4,11).
The quantification of drooling can be performed using 
various methods, such as the drainage or expectoration 
techniques or collection using a salivary ejector (12). These 
methods provide an objective evaluation of the quantity 
of saliva produced (10,11), but the limited collaboration 
in disabled patients requires the use of alternative methods 
of  quantification. As in the present case, the majority 
of studies published use clinical scales of quantification 
(13,14), limiting the objectivity of the results obtained.
In this patient, the scopolamine patches were effective in 
reducing saliva production. Comparing scopolamine with 
placebo, Brodtkorb et al. (13) achieved a significant reduc-
tion in drooling at 24, 48 and 72 hours after application 
of the patch in 15 patients between 20 and 62 years of age 
with mental retardation and with problems of continual 
drooling (13). This result was also observed in 11 chil-
dren with mental retardation with a moderate-to-severe 
degree of drooling (14). Dreyfuss et al. (10) reported a 
30% reduction in drooling in a 40-year-old, brain-dama-
ged patient after placement of a single scopolamine skin 
patch, and a 59% reduction after applying two patches 
simultaneously.
Pupillary dilatation and urinary retention are some of the 
most common undesirable effects of scopolamine patches. 
Lewis et al. (14) observed that 66% of patients presented 
pupillary dilatation and that this occurred within a few 
days of starting treatment. Talmi et al (11), in a study of 
12 patients treated with transdermal scopolamine for short 
periods of time (1-6 days), reported 4 cases of blurred 
vision and one of urinary retention that required inte-
rruption of the treatment. The findings of these and other 
studies suggest that the majority of adverse effects develop 
within the first hours/days of treatment. In our case, the 
patient has presented signs of incipient urinary retention, 
though this has not become an adverse reaction requiring 
the temporary or definitive withdrawal of the treatment. 
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Other effects are described in the literature with lower 
frequencies, including tachycardia, anxiety, disorientation, 
hallucinations, psychosis, blurred vision and pruritus in 
the area of application of the patch (2,4,5).
There is no method of control of drooling that has been 
found to be effective in all patients. Anticholinergic drugs 
such as scopolamine are effective in the treatment of 
drooling but, according to Jongerius et al (15), it has not 
been established which is the most effective drug. Although 
it has been shown that scopolamine patches can be a useful 
option in the treatment of these patients, their efficacy 
varies between patients. We have found no prospective 
studies in the literature that evaluate its long-term effects; 
the studies of longest duration were 4-5 months (10,14). 
In our patient, transdermal scopolamine was an effective 
and safe method for reducing the drooling; however, the 
study population and the follow-up time will have to be 
increased in order to confirm its validity as a treatment 
for long-term use.
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